{"symbol":"MRK","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"BMO","status":"upcoming","company":{"name":"Merck & Co., Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/MRK/earnings/Q2-2026","estimates":{"consensusEps":-0.2576,"consensusRevenue":16365.67,"epsLow":-0.4,"epsHigh":-0.0258,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Merck & Co., Inc. (MRK) is a global healthcare company that develops and produces pharmaceuticals, vaccines, and animal health products. With a market cap of $321 billion, it plays a crucial role in the healthcare sector, particularly in areas like oncology, infectious diseases, and vaccines.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and will show how well the company is managing costs and revenues this quarter.","consensus":"-0.26"},{"name":"Revenue","why":"Revenue reflects the overall sales performance and demand for Merck's products, which is critical for assessing growth.","consensus":"16.4B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Merck reported an EPS of -1.28, beating expectations by 15.46%. However, the stock fell 1.60% the following day, indicating potential market concerns despite the positive surprise.","promises":[]},"wallStreetExpectations":{"summary":"Analysts are cautiously optimistic about Merck's upcoming earnings, with expectations for a slight revenue increase but a negative EPS. The market is watching closely for any signs of recovery or continued challenges.","bullCase":"If Merck can exceed EPS expectations and show strong revenue growth, it could signal a turnaround in profitability and boost investor confidence.","bearCase":"Conversely, if the company reports a larger-than-expected loss or lower revenue, it could raise concerns about its ability to compete and innovate in the pharmaceutical sector."},"optionsSignal":{"impliedMove":"11.56%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+15.46%","reaction":"-1.60%"},{"quarter":"Q4-2025","epsSurprise":"+0.59%","reaction":"+2.18%"},{"quarter":"Q3-2025","epsSurprise":"+9.32%","reaction":"-0.35%"},{"quarter":"Q2-2025","epsSurprise":"+4.67%","reaction":"-1.70%"},{"quarter":"Q1-2025","epsSurprise":"+3.06%","reaction":"+1.40%"}],"pivotalQuestions":[{"question":"Will Merck's revenue meet or exceed the consensus estimate of $16.4 billion?","whyItMatters":"Revenue performance will be critical in assessing the company's growth trajectory and market demand for its products."},{"question":"What specific factors contributed to the expected EPS of -0.26?","whyItMatters":"Understanding the drivers behind the EPS forecast will help investors gauge the company's operational efficiency and cost management."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $-0.03 or better would confirm the bull case, indicating strong cost management and demand.","bearTrigger":"An EPS worse than $-0.40 would confirm the bear case, suggesting deeper issues in profitability.","context":"The upcoming earnings report is pivotal as it will reveal whether Merck can stabilize its financial performance amidst market challenges."},"scenarioPlaybook":{"beatAndRaise":"If Merck beats expectations, history suggests a potential average one-day move of +2.67%, confirming a positive outlook.","inLineCautious":"If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.","miss":"A miss could lead to a decline, with historical patterns indicating an average one-day move down of -1.60%."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Merck's potential for a turnaround, as recent product launches could drive unexpected revenue growth.","supportingPoints":["The options market is pricing in a significant move, indicating traders expect volatility that may not align with consensus.","Merck's history of beating EPS estimates suggests that analysts may be overly cautious this quarter."],"riskToConsensus":"If revenue exceeds $16.6 billion, it could challenge the current bearish sentiment and shift market perception."},"whatToListenFor":["Any updates on new product launches and their expected impact on revenue.","Management's commentary on cost management strategies and operational efficiency.","Insights into market demand for key products, especially in oncology and vaccines.","Any guidance on future quarters that could indicate a turnaround in profitability.","Responses to competitive pressures in the pharmaceutical industry."],"metaDescription":"Merck (MRK) reports Q2 2026 earnings on August 4. Analysts expect a loss of $0.26 EPS on $16.4B revenue. Here's what to watch."}}